Drug Profile
IT 1208
Alternative Names: IT-1208Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Kyowa Hakko Kirin
- Developer IDAC Theranostics
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD4 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections; Solid tumours
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Japan (Parenteral)
- 28 Jul 2021 No recent reports of development identified for research development in HIV-infections in Japan (Parenteral)
- 08 May 2019 Efficacy results from the trial were presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)